{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T10:28:28Z","timestamp":1776162508013,"version":"3.50.1"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2021,2,8]],"date-time":"2021-02-08T00:00:00Z","timestamp":1612742400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,2,8]],"date-time":"2021-02-08T00:00:00Z","timestamp":1612742400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Drugs Ther"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1007\/s10557-020-07137-z","type":"journal-article","created":{"date-parts":[[2021,2,9]],"date-time":"2021-02-09T10:59:29Z","timestamp":1612868369000},"page":"301-308","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["LDL Cholesterol Reduction Variability with Different Types and Doses of Statins in Monotherapy or Combined with Ezetimibe. Results from the Spanish Arteriosclerosis Society Dyslipidaemia Registry"],"prefix":"10.1007","volume":"36","author":[{"given":"Elisenda","family":"Climent","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana M.","family":"Bea","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Benaiges","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00c1ngel","family":"Brea-Hernando","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xavier","family":"Pint\u00f3","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuel","family":"Su\u00e1rez-Tembra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ver\u00f3nica","family":"Perea","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N\u00faria","family":"Plana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco","family":"Blanco-Vaca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan","family":"Pedro-Botet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"on behalf of the Dyslipidaemia Registry of the Spanish Atherosclerosis Society","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,2,8]]},"reference":[{"issue":"1","key":"7137_CR1","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1093\/eurheartj\/ehz455","volume":"41","author":"F Mach","year":"2020","unstructured":"Mach F, Baigent C, Catapano AL, ESC Scientific Document Group, et al. 2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):1118\u201388.","journal-title":"Eur Heart J"},{"issue":"3","key":"7137_CR2","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1016\/j.recesp.2015.11.016","volume":"69","author":"L Masana","year":"2016","unstructured":"Masana L, Ibarretxe D, Plana N. Maximum low-density lipoprotein cholesterol lowering capacity achievable with drug combinations. When 50 plus 20 equals 60. Rev Esp Cardiol (Engl Ed). 2016;69(3):342\u20133.","journal-title":"Rev Esp Cardiol (Engl Ed)"},{"issue":"8","key":"7137_CR3","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1177\/2047487318825350","volume":"26","author":"K Kotseva","year":"2019","unstructured":"Kotseva K, De Backer G, De Bacquer D, EUROASPIRE Investigators, et al. Lifestyle and impact on cardiovascular risk factor control in coronary patients across 27 countries: results from the European Society of Cardiology ESC-EORP EUROASPIRE V registry. Eur J Prev Cardiol. 2019;26(8):824\u201335.","journal-title":"Eur J Prev Cardiol"},{"key":"7137_CR4","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.thromres.2019.09.034","volume":"183","author":"J Sundb\u00f8ll","year":"2019","unstructured":"Sundb\u00f8ll J, Larsen AP, Veres K, Adelborg K, S\u00f8rensen HT. Cardiovascular event rates and trajectories of LDL-cholesterol levels and lipid-lowering therapy in patients with atherosclerotic cardiovascular disease: a population-based cohort study. Thromb Res. 2019;183:124\u201330.","journal-title":"Thromb Res"},{"key":"7137_CR5","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.atherosclerosis.2016.09.004","volume":"255","author":"AK Gitt","year":"2016","unstructured":"Gitt AK, Lautsch D, Ferrieres J, Kastelein J, Drexel H, Horack M, et al. Low-density lipoprotein cholesterol in a global cohort of 57,885 statin-treated patients. Atherosclerosis. 2016;255:200\u20139.","journal-title":"Atherosclerosis."},{"issue":"9493","key":"7137_CR6","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1016\/S0140-6736(05)67394-1","volume":"366","author":"C Baigent","year":"2005","unstructured":"Baigent C, Keech A, Kearney PM, Cholesterol Treatment Trialists\u2019 (CTT) Collaborators, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366(9493):1267\u201378.","journal-title":"Lancet."},{"issue":"9753","key":"7137_CR7","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","volume":"376","author":"C Baigent","year":"2010","unstructured":"Cholesterol Treatment Trialists\u2019(CTT) Collaboration, Baigent C, Blackwell L, Emberson J, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376(9753):1670\u201381.","journal-title":"Lancet."},{"issue":"9841","key":"7137_CR8","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/S0140-6736(12)60367-5","volume":"380","author":"B Mihaylova","year":"2012","unstructured":"Cholesterol Treatment Trialists\u2019 (CTT) Collaborators, Mihaylova B, Emberson J, Blackwell L, et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet. 2012;380(9841):581\u201390.","journal-title":"Lancet."},{"issue":"10170","key":"7137_CR9","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/S0140-6736(18)31942-1","volume":"393","author":"Cholesterol Treatment Trialists\u2019 Collaboration","year":"2019","unstructured":"Cholesterol Treatment Trialists\u2019 Collaboration. Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials. Lancet. 2019;393(10170):407\u201315.","journal-title":"Lancet."},{"issue":"5","key":"7137_CR10","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/j.jacc.2014.02.615","volume":"64","author":"SM Boekholdt","year":"2014","unstructured":"Boekholdt SM, Hovingh GK, Mora S, Arsenault BJ, Amarenco P, Pedersen TR, et al. Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: a meta-analysis of statin trials. J Am Coll Cardiol. 2014;64(5):485\u201394.","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"7137_CR11","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1016\/j.atherosclerosis.2015.03.004","volume":"240","author":"O Descamps","year":"2015","unstructured":"Descamps O, Tomassini JE, Lin J, Polis AB, Shah A, Brudi P, et al. Variability of the LDL-C lowering response to ezetimibe and ezetimibe + statin therapy in hypercholesterolemic patients. Atherosclerosis. 2015;240(2):482\u20139.","journal-title":"Atherosclerosis."},{"issue":"17","key":"7137_CR12","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1093\/eurheartj\/ehw046","volume":"37","author":"PM Ridker","year":"2016","unstructured":"Ridker PM, Mora S, Rose L, JUPITER Trial Study Group. Percent reduction in LDL cholesterol following high-intensity statin therapy: potential implications for guidelines and for the prescription of emerging lipid-lowering agents. Eur Heart J. 2016;37(17):1373\u20139.","journal-title":"Eur Heart J"},{"issue":"1","key":"7137_CR13","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/S0021-9150(01)00410-5","volume":"158","author":"J Pedro-Botet","year":"2001","unstructured":"Pedro-Botet J, Schaefer EJ, Bakker-Arkema RG, Black DM, Stein EM, Corella D, et al. Apolipoprotein E genotype affects plasma lipid response to atorvastatin in a gender specific manner. Atherosclerosis. 2001;158(1):183\u201393.","journal-title":"Atherosclerosis."},{"issue":"23","key":"7137_CR14","doi-asserted-by":"publisher","first-page":"2821","DOI":"10.1001\/jama.291.23.2821","volume":"291","author":"DI Chasman","year":"2004","unstructured":"Chasman DI, Posada D, Subrahmanyan L, Cook NR, Stanton VP Jr, Ridker PM. Pharmacogenetic study of statin therapy and cholesterol reduction. JAMA. 2004;291(23):2821\u20137.","journal-title":"JAMA."},{"issue":"6","key":"7137_CR15","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1016\/j.amjcard.2005.09.134","volume":"97","author":"JA Simon","year":"2006","unstructured":"Simon JA, Lin F, Hulley SB, Blanche PJ, Waters D, Shiboski S, et al. Phenotypic predictors of response to simvastatin therapy among African-Americans and Caucasians: the Cholesterol and Pharmacogenetics (CAP) study. Am J Cardiol. 2006;97(6):843\u201350.","journal-title":"Am J Cardiol"},{"issue":"3","key":"7137_CR16","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.amjcard.2016.10.037","volume":"119","author":"S Bangalore","year":"2017","unstructured":"Bangalore S, Fayyad R, Messerli FH, Laskey R, DeMicco DA, Kastelein JJP, et al. Relation of variability of low-density lipoprotein cholesterol and blood pressure to events in patients with previous myocardial infarction from the IDEAL trial. Am J Cardiol. 2017;119(3):379\u201387.","journal-title":"Am J Cardiol"},{"issue":"3","key":"7137_CR17","doi-asserted-by":"publisher","first-page":"3242","DOI":"10.18632\/oncotarget.23228","volume":"9","author":"YH Lin","year":"2017","unstructured":"Lin YH, Huang JC, Wu PY, et al. Greater low-density lipoprotein cholesterol variability is associated with increased progression to dialysis in patients with chronic kidney disease stage 3. Oncotarget. 2017;9(3):3242\u201353.","journal-title":"Oncotarget."},{"issue":"2","key":"7137_CR18","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1111\/j.1365-2710.2009.01085.x","volume":"35","author":"TC Weng","year":"2010","unstructured":"Weng TC, Yang YH, Lin SJ, Tai SH. A systematic review and meta-analysis on the therapeutic equivalence of statins. J Clin Pharm Ther. 2010;35(2):139\u201351.","journal-title":"J Clin Pharm Ther"},{"issue":"4","key":"7137_CR19","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1194\/jlr.P800042-JLR200","volume":"50","author":"TM van Himbergen","year":"2009","unstructured":"van Himbergen TM, Matthan NR, Resteghini NA, Otokozawa S, Ai M, Stein EA, et al. Comparison of the effects of maximal dose atorvastatin and rosuvastatin therapy on cholesterol synthesis and absorption markers. J Lipid Res. 2009;50(4):730\u20139.","journal-title":"J Lipid Res"},{"issue":"4","key":"7137_CR20","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1093\/ehjcvp\/pvw006","volume":"2","author":"BW Karlson","year":"2016","unstructured":"Karlson BW, Wiklund O, Palmer MK, Nicholls SJ, Lundman P, Barter PJ. Variability of low-density lipoprotein cholesterol response with different doses of atorvastatin, rosuvastatin, and simvastatin: results from VOYAGER. Eur Heart J Cardiovasc Pharmacother. 2016;2(4):212\u20137.","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"issue":"6","key":"7137_CR21","first-page":"248","volume":"29","author":"S P\u00e9rez-Calahorra","year":"2017","unstructured":"P\u00e9rez-Calahorra S, S\u00e1nchez-Hern\u00e1ndez RM, Plana N, Valdivielso P, Civeira F. National dyslipidemia registry of the Spanish Arteriosclerosis Society: current status. Clin Invest Arterioscler. 2017;29(6):248\u201353.","journal-title":"Clin Invest Arterioscler"},{"issue":"45","key":"7137_CR22","doi-asserted-by":"publisher","first-page":"3478","DOI":"10.1093\/eurheartj\/eht273","volume":"34","author":"BG Nordestgaard","year":"2013","unstructured":"Nordestgaard BG, Chapman MJ, Humphries SE, European Atherosclerosis Society Consensus Panel, et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. Eur Heart J. 2013;34(45):3478\u201390.","journal-title":"Eur Heart J"},{"issue":"7","key":"7137_CR23","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/j.recesp.2018.01.004","volume":"71","author":"J Pedro-Botet","year":"2018","unstructured":"Pedro-Botet J, Rodr\u00edguez-Padial L, Brotons C, Esteban-Sal\u00e1n M, Garc\u00eda-Ler\u00edn A, Pint\u00f3 X, et al. The ideal lipid report: a need for consensus. Rev Esp Cardiol (Engl Ed). 2018;71(7):512\u20134.","journal-title":"Rev Esp Cardiol (Engl Ed)"},{"issue":"5","key":"7137_CR24","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1016\/S0002-9149(97)00965-X","volume":"81","author":"P Jones","year":"1998","unstructured":"Jones P, Kafonek S, Laurora I, Hunninghake D. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study). Am J Cardiol. 1998;81(5):582\u20137.","journal-title":"Am J Cardiol"},{"issue":"3","key":"7137_CR25","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/s40256-019-00379-9","volume":"20","author":"FT Shaya","year":"2020","unstructured":"Shaya FT, Sing K, Milam R, Husain F, Del Aguila MA, Patel MY. Lipid-lowering efficacy of ezetimibe in patients with atherosclerotic cardiovascular disease: a systematic review and meta-analyses. Am J Cardiovasc Drugs. 2020;20(3):239\u201348.","journal-title":"Am J Cardiovasc Drugs"},{"issue":"2","key":"7137_CR26","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.atherosclerosis.2012.02.016","volume":"223","author":"D Morrone","year":"2012","unstructured":"Morrone D, Weintraub WS, Toth PP, Hanson ME, Lowe RS, Lin J, et al. Lipid-altering efficacy of ezetimibe plus statin and statin monotherapy and identification of factors associated with treatment response: a pooled analysis of over 21,000 subjects from 27 clinical trials. Atherosclerosis. 2012;223(2):251\u201361.","journal-title":"Atherosclerosis."},{"issue":"1","key":"7137_CR27","doi-asserted-by":"publisher","first-page":"13","DOI":"10.2217\/clp.12.88","volume":"8","author":"A Catapano","year":"2013","unstructured":"Catapano A, Toth PP, Tomassini JE, Tershakovec AM. The efficacy and safety of ezetimibe coadministered with statin therapy in various patient groups. Clin Lipidol. 2013;8(1):13\u201341.","journal-title":"Clin Lipidol"},{"key":"7137_CR28","doi-asserted-by":"publisher","first-page":"34","DOI":"10.7775\/rac.es.v82.i1.2882","volume":"82","author":"M Masson","year":"2014","unstructured":"Masson M, Lobo M, Maenent D, et al. Response to statins in cardiovascular prevention: hypo-responders\u2019 evaluation. Rev Argent Cardiol. 2014;82:34\u201341.","journal-title":"Rev Argent Cardiol"},{"issue":"5","key":"7137_CR29","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1016\/j.mcna.2011.06.003","volume":"95","author":"R Franssen","year":"2011","unstructured":"Franssen R, Monajemi H, Stroes ES, Kastelein JJ. Obesity and dyslipidemia. Med Clin North Am. 2011;95(5):893\u2013902.","journal-title":"Med Clin North Am"}],"container-title":["Cardiovascular Drugs and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-020-07137-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10557-020-07137-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-020-07137-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,22]],"date-time":"2022-03-22T10:19:59Z","timestamp":1647944399000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10557-020-07137-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,8]]},"references-count":29,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["7137"],"URL":"https:\/\/doi.org\/10.1007\/s10557-020-07137-z","relation":{},"ISSN":["0920-3206","1573-7241"],"issn-type":[{"value":"0920-3206","type":"print"},{"value":"1573-7241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,8]]},"assertion":[{"value":"23 December 2020","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 February 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Anonymous clinical data collection in this registry was approved by a central ethics committee (Comit\u00e9 \u00c9tico de Investigaci\u00f3n Cl\u00ednica de Arag\u00f3n, Zaragoza, Spain). Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval and Consent to Participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Sanofi had no role in the study design, data collection, analysis, interpretation, report writing, or decision to submit for publication.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclaimer"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}}]}}